Search

Sunil D Chada

from Missouri City, TX
Age ~65
Get Report
Also known as:
Sunil C Chada, Sunil L Chada
Phone and address:
4007 Waterview Ct, Missouri City, TX 77459
(281) 403-6240
Related to:
Misha Dylan Chada, 28Shannan A Sligar, 46Sasha A Chada, 33Richard Michael Kinert, 61Richard O Felser, 79Barbara S WachtelSharon F Felser, 80Sharon W Chada, 64
Connected to:
Karteek R Chada, 48Nancy M Chada, 71Deepak Chadaga, 55Jyothika Chadaga, 54Richard L Chadakoff, 79Ahalya R Chadalavada, 56Theja Chadalawada, 33John M Chadam, 85Shilpa S Chadar, 37Cortez J Chadarius, 29

Sunil Chada Phones & Addresses

  • 4007 Waterview Ct, Missouri City, TX 77459 (281) 403-6240 (281) 403-9585
  • Austin, TX
  • 1542 Enchantment Ave, Vista, CA 92083 (760) 598-5851
  • Stafford, TX
  • Shrewsbury, MA
  • 4007 Waterview Ct, Missouri City, TX 77459 (281) 403-6240

Work

Company: Dnasolve 2011 Address: Houston, TX Position: President

Education

Degree: Ph.D. School / High School: University of Massachusetts Medical School, Worcester, MA 1989 Specialities: Department of Molecular Genetics and Microbiology

Skills

Biotechnology • Drug Development • Cancer • Clinical Development • Oncology • Biopharmaceuticals • Lifesciences • Cell • Immunology • Regulatory Affairs • Molecular Biology • Drug Discovery • Technology Transfer • Biomarkers • Drug Delivery • Vaccines • Clinical Trials • Genetics • Translational Medicine • Glp • In Vivo • Infectious Diseases • Biochemistry • Ind • Elisa • Clinical Research • Toxicology • Cell Biology • Immunoassays • Microbiology • Monoclonal Antibodies • Pharmaceutical Industry • Synthetic Biology • In Vitro • Commercialization • Inflammation • Genomics • Protein Chemistry • Cell Culture • Fda • Translational Research • Assay Development • Antibodies • Pharmacology • Virology • Pcr • Flow Cytometry • Gene Therapy • T Cell Engineering • Car T Cells

Emails

s***[email protected]

Industries

Biotechnology

Resumes

Resumes

Sunil Chada Photo 1

President

View page
Location:
4007 Waterview Ct, Missouri City, TX 77459
Industry:
Biotechnology
Work:
DNAsolve - Houston, TX since 2011
President
Intrexon Corporation - Blacksburg, VA 2008 - 2011
Senior Vice President, Translational Medicine
Introgen Therapeutics, Houston TX - Houston, TX 1997 - 2008
Associate VP, Clinical Research
Chiron-Viagene - San Diego, CA 1988 - 1997
Staff Scientist
Education:
University of Massachusetts Medical School, Worcester, MA 1989
Ph.D., Department of Molecular Genetics and Microbiology University of California at Los Angeles, Los Angeles, CA 1985
M.Sc., Molecular Biology Kings College, University of London, United Kingdom 1982
B.Sc. (honors), Department of Cell and Molecular Biology
Skills:
Biotechnology
Drug Development
Cancer
Clinical Development
Oncology
Biopharmaceuticals
Lifesciences
Cell
Immunology
Regulatory Affairs
Molecular Biology
Drug Discovery
Technology Transfer
Biomarkers
Drug Delivery
Vaccines
Clinical Trials
Genetics
Translational Medicine
Glp
In Vivo
Infectious Diseases
Biochemistry
Ind
Elisa
Clinical Research
Toxicology
Cell Biology
Immunoassays
Microbiology
Monoclonal Antibodies
Pharmaceutical Industry
Synthetic Biology
In Vitro
Commercialization
Inflammation
Genomics
Protein Chemistry
Cell Culture
Fda
Translational Research
Assay Development
Antibodies
Pharmacology
Virology
Pcr
Flow Cytometry
Gene Therapy
T Cell Engineering
Car T Cells

Business Records

Name / Title
Company / Classification
Phones & Addresses
Sunil Chada
Director
PSYGEN, LLC
4007 Waterview Ct, Missouri City, TX 77459
2855 Commercial Ctr Blvd, Katy, TX 77494

Publications

Us Patents

Method For Inhibiting Human Tumor Cells

View page
US Patent:
6410326, Jun 25, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/486683
Inventors:
Harry E. Gruber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
Jack R. Barber - San Diego CA
Daniel C. St. Louis - Rockville MD
Sunil D. Chada - Vista CA
Stephen M. W. Chang - San Diego CA
John F. Warner - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C12N 1563
US Classification:
435455
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Antihelminthic Drugs As A Treatment For Hyperproliferative Diseases

View page
US Patent:
7423015, Sep 9, 2008
Filed:
Jan 9, 2002
Appl. No.:
10/043877
Inventors:
Tapas Mukhopadhyay - Houston TX, US
Sunil Chada - Missouri City TX, US
Abner Mhashilkar - Houston TX, US
Jack A. Roth - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
Introgen Therapeutics, Inc. - Austin TX
International Classification:
A01K 43/78
US Classification:
514 12, 514365, 514396, 514397, 514388
Abstract:
The present invention is directed to the use of benzimidazole derivatives for the treatment of tumors and in combination with tumor suppressor gene therapy. In a particular embodiment, treatment of p53-positive tumors with benzimidazole derivatives induces p53 expression and increases its half-life, resulting in apoptotic death of the tumor cells. Similarly, in conjunction with p53 gene therapy, benzimidazole derivatives induce p53 expression and accumulation in tumor cells regardless of their p53 status. The combination treatment subsequently elicits apoptosis of the tumor cells.

Use Of Mda-7 To Inhibit Pathogenic Infectious Organisms

View page
US Patent:
8034790, Oct 11, 2011
Filed:
Dec 1, 2004
Appl. No.:
11/001702
Inventors:
Sunil Chada - Missouri City TX, US
Assignee:
Introgen Therapeutics - Austin TX
International Classification:
A61K 38/20
A61K 48/00
US Classification:
514 44R, 514 37, 424 852
Abstract:
Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.

Non-Immunogenic Prodrugs And Selectable Markers For Use In Gene Therapy

View page
US Patent:
20020082224, Jun 27, 2002
Filed:
Jan 13, 1998
Appl. No.:
09/006298
Inventors:
DOUGLAS J. JOLLY - LEUCADIA CA, US
MARGARET D. MOORE - SAN DIEGO CA, US
SUNIL CHADA - VISTA CA, US
International Classification:
A61K048/00
US Classification:
514/044000, 424/093100, 435/320100
Abstract:
The present invention provides methods for delivering a gene delivery vehicle to a warm-blooded animal, comprising the step of administering to a warm-blooded animal a gene delivery vehicle which directs the expression of a non-immunogenic selectable marker. Within other aspects, methods are provided for delivering a gene delivery vehicle to a warm-blooded animal, comprising the step of administering to a warm-blooded animal a gene delivery vehicle which directs the expression of a non-immunogenic molecule which is capable of activating an otherwise inactive compound into an active compound.

Immunostimulation Mediated By Gene-Modified Dendritic Cells

View page
US Patent:
20020123479, Sep 5, 2002
Filed:
Oct 12, 2001
Appl. No.:
09/976576
Inventors:
Elizabeth Song - Howth, IE
Sunil Chada - Vista CA, US
Virginia Lee - Cardiff CA, US
Douglas Jolly - Leucadia CA, US
International Classification:
A61K048/00
A61K039/395
C12N007/01
C12N015/867
US Classification:
514/044000, 435/456000, 424/093210, 435/235100, 424/144100
Abstract:
Compositions and methods useful for stimulating an immune response against one or more disease associated antigens by genetically modifying dendritic cells in vivo or ex vivo are provided. These compositions and methods allow for administration of lower dosages of gene delivery vehicles in order to achieve levels of immune stimulation comparable to those obtainable by conventional methods. Alternatively, administration of conventional dosages of gene delivery vehicles will enhance the resultant immune response.

Methods Of Treatment Involving Human Mda-7

View page
US Patent:
20020183271, Dec 5, 2002
Filed:
Dec 7, 2001
Appl. No.:
10/017472
Inventors:
Sunil Chada - Missouri City TX, US
Elizabeth Grimm - Houston TX, US
Abner Mhashilkar - Houston TX, US
Rajagopal Ramesh - Sugarland TX, US
International Classification:
A61K048/00
A61K038/43
US Classification:
514/044000, 424/094100
Abstract:
The present invention relates to gene therapy methods for the treatment of human disease. More specifically, the invention is directed to methods for treating a subject with an angiogenesis-related disease. In one embodiment, an adenoviral expression construct comprising a nucleic acid encoding a human MDA-7 protein under the control of a promoter operable in eukaryotic cells, is administered to said patient with an angiogenesis-related disease. The present invention thus provides for treatment of angiogenesis-related disease by through expression of mda-7 and inhibition angiogenesis. Such diseases include cancer.

Dendritic Cells Transduced With A Wild-Type Self Gene Elicit Potent Antitumor Immune Responses

View page
US Patent:
20030045499, Mar 6, 2003
Filed:
Aug 9, 2002
Appl. No.:
10/216346
Inventors:
Dmitry Gabrilovich - Aurora IL, US
David Carbone - Franklin TN, US
Sunil Chada - Missouri City TX, US
Abner Mhashilkar - Houston TX, US
Assignee:
Vanderbilt University and Introgen Therapeutics, Inc.
International Classification:
A61K048/00
US Classification:
514/044000
Abstract:
The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increased or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells. The present invention thus provides immunotherapies for treating hyperproliferative and pathogen diseases by attenuating the natural immune systems CTL response against hyperproliferative cells or overexpressing mutant p53 antigens.

Adenoviral P53 Gene Transfer In The Prevention And Treatment Of Injury-Induced Vascular Smooth Muscle Cell Proliferation

View page
US Patent:
20030223967, Dec 4, 2003
Filed:
May 9, 2003
Appl. No.:
10/434693
Inventors:
Louis Zumstein - Houston TX, US
Sunil Chada - Missouri City TX, US
International Classification:
A61K048/00
C12N007/00
C12N015/86
US Classification:
424/093200, 435/235100, 435/456000
Abstract:
The present invention provides for the use of expression constructs encoding the tumor suppressor p53 for the prevention or treatment of vascular stenosis caused by vascular smooth muscle cell (VSMC) proliferation and/or migration in response to vascular trauma. This p53 therapy may be used in conjunction with other therapies including secondary gene therapy, anti-thrombotics or anti-inflammatory agents.
Control profile
Sunil D Chada from Missouri City, TX, age ~65 Get Report